NCT05205668 is a Phase 2 clinical trial of F-652 in COVID-19 Pneumonia, sponsored by EVIVE Biotechnology.

Who is sponsoring NCT05205668?

NCT05205668 is sponsored by EVIVE Biotechnology.

What drugs are being tested in NCT05205668?

Interventions in NCT05205668: F-652, Placebo.

What condition does NCT05205668 study?

NCT05205668 studies COVID-19 Pneumonia.

Is NCT05205668 still recruiting?

NCT05205668 is currently withdrawn. Last updated 2 October 2023.

Last reviewed 2023-10-02 · How we verify

NCT05205668

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia

Withdrawn Phase 2 Last updated 2 October 2023

What this trial tests

Phase 2 trial testing F-652 in COVID-19 Pneumonia. Withdrawn.

Timeline

8 April 2022

Primary endpoint
8 April 2022

8 April 2023

Quick facts

Lead sponsor	EVIVE Biotechnology
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Start date	8 April 2022
Primary completion	8 April 2022
Estimated completion	8 April 2023

Drugs / interventions tested

F-652 — full drug profile →
Placebo

Conditions studied

COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →

Sponsor

EVIVE Biotechnology — full company profile →

Who can join

18 and older, any sex, with COVID-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 2a, multicenter, randomized, double-blinded, placebo controlled, dose escalation study in adult subjects with COVID-19 pneumonia. The primary objective of this study is to evaluate the overall safety of F-652 in COVID subjects in order to identify safe dose(s) for future studies with adequate patient numbers to demonstrate clinical efficacy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Novel treatment of acute and acute-on-chronic liver failure: Interleukin-22.
Hwang S, Hicks A, Hoo CZ, Kwon YS, et al · · 2025 · cited 15× · PMID 37208937 · DOI 10.1111/liv.15619

Verify or expand the search:

Other trials of F-652

Trials testing the same drug.

NCT04498377 — Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19 · Phase 2 · terminated

Other recruiting trials for COVID-19 Pneumonia

Currently open trials in the same condition.

NCT06601998 — Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. · recruiting
NCT06501599 — AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes · recruiting
NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting

Other EVIVE Biotechnology trials

Trials by the same sponsor.

NCT04498377 — Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19 · Phase 2 · terminated
NCT04056975 — Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma · Phase 1 · unknown
NCT03252431 — Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy · Phase 3 · completed
NCT04174599 — Study to Compare the Efficacy and Safety of F-627 and GRAN® · Phase 3 · completed
NCT02406651 — Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05205668 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EVIVE Biotechnology
Last refreshed: 2 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05205668.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing